Skip to main content

The rockefeller university

News & HighlightsNews
Displaying 164 of 2907 articles.
The common thread in severe COVID-19 
New studies point to a single molecular explanation for 20 percent of critical COVID-19 cases: insufficient or defective type I interferons.
Hunting for TB's most vulnerable genes
Not every gene that's essential in tuberculosis is also vulnerable to attack. A new study ranks essential genes by vulnerability, allowing researchers to better prioritize future drug targets.
Putting the brakes on immune reactions
Helper T cells may play a dual role in the immune system, both encouraging and suppressing the process by which B cells mature.
How CRISPR promotes antibiotic resistance in bacteria
Whenever a cell uses CRISPR to defend itself, there's a chance of mutations creeping into its genetic code. Some of these mutations are harmless; others kill the cell. But fortuitous mutations can occasionally render major human pathogens, such as Staphylococcus aureus, antibiotic resistant.
Vaccines charge up natural immunity against SARS-CoV-2
Vaccination enhances antibodies in people who have had COVID, likely giving them protection even from the new variants.
Brain disease transmitted by tick bites may be treatable
The virus that causes tick-borne encephalitis appears to trick the immune system, misdirecting it into producing inferior antibodies. But new research shows some people produce more potent antibodies, providing hope for treatment.
Immunologist Daniel Mucida promoted to professor
A pioneer in the field of mucosal immunology, Mucida is unlocking the secrets of the digestive system and answering fundamental questions about the origins of human disease.
How one patient’s rare mutation helped solve a mycobacterial mystery
The discovery may explain why some patients suffer more severe reactions than others—putting us one step closer to understanding how our DNA influences our susceptibility to a wide range of infectious diseases.
Rockefeller grants commercial license for the development of monoclonal antibodies for treatment of COVID-19
The treatment, a combination of two antibodies, has been shown highly capable of neutralizing SARS-CoV-2 in preclinical studies. Researchers hope it will give countries around the world, including developing countries, a way to control the rampant disease.
COVID-19 vaccines may need regular updates for emerging variants
Lab experiments suggest that the new strains reported in Britain, South Africa, and Brazil may blunt the potency of the Pfizer and Moderna COVID-19 vaccines. This could mean that the vaccines will need updates as the virus mutates.
View
View